CSBR250117C10000
- 2.15
- 0.000.00%
Champions Oncology Newsroom
Momentum Reigned 2024: Buy-rated U.S. Stocks With the Highest RSI
Private Equity Firms Invested in Champions Oncology, Inc. (NASDAQ:CSBR) up 19% Last Week, Insiders Too Were Rewarded
Top Premarket Decliners
Champions Oncology | 10-Q: Q2 2025 Earnings Report
Further Upside For Champions Oncology, Inc. (NASDAQ:CSBR) Shares Could Introduce Price Risks After 38% Bounce
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8
Champions Oncology Analyst Ratings
Express News | Champions Oncology Inc : Craig-Hallum Raises Target Price to $8 From $6
Stocks to Watch: Adobe, Champions Oncology, DBV Technologies
Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript
Express News | Champions Oncology Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q2 Financial Results
Earnings Flash (CSBR) CHAMPIONS ONCOLOGY Reports Q2 EPS $0.05, Vs. Street Est of $0.01
Express News | Champions Oncology Q2 Revenue USD 13.5 Million
Express News | Champions Oncology Q2 Adjusted Ebitda USD 1.1 Million
Express News | Champions Oncology Q2 EPS USD 0.05
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
Earnings Scheduled For December 11, 2024
A Peek at Champions Oncology's Future Earnings
Craig-Hallum Maintains Champions Oncology(CSBR.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Ascendis Pharma (ASND) and Champions Oncology (CSBR)